Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review
Introduction Infant immunization programs using pneumococcal conjugate vaccines (PCVs) have reduced the rates of pneumococcal disease through direct vaccine-induced protection in vaccinated children and through indirect protection in non-vaccinated children and adults.Areas covered This review summa...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2416229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141449552265216 |
|---|---|
| author | Elmira Flem Celine Mouawad Arto A. Palmu Heather Platt Kelly D. Johnson E. David McIntosh Jacobo Abadi Ulrike K. Buchwald Kristen Feemster |
| author_facet | Elmira Flem Celine Mouawad Arto A. Palmu Heather Platt Kelly D. Johnson E. David McIntosh Jacobo Abadi Ulrike K. Buchwald Kristen Feemster |
| author_sort | Elmira Flem |
| collection | DOAJ |
| description | Introduction Infant immunization programs using pneumococcal conjugate vaccines (PCVs) have reduced the rates of pneumococcal disease through direct vaccine-induced protection in vaccinated children and through indirect protection in non-vaccinated children and adults.Areas covered This review summarizes current evidence on the indirect protection of adults conferred by pediatric pneumococcal vaccination, including the impact on invasive pneumococcal disease (IPD) incidence and mortality, pneumonia admissions, and nasopharyngeal carriage prevalence. Factors affecting indirect protection against IPD are also discussed.Expert opinion Pediatric immunization with PCVs has substantially decreased vaccine-serotype IPD and pneumonia through indirect protection in both older (≥65 years of age) and younger adults, including those with underlying medical conditions. However, serotype replacement by non-vaccine serotypes, the persistence of some vaccine serotypes, and divergence of serotypes between children and adults have limited the impact of pediatric PCV programs on adult populations. Designing complementary vaccines that leverage indirect protection from pediatric immunization and target the most prevalent adult serotypes may be a preferred strategy to maximize the public health impact of pneumococcal vaccination. |
| format | Article |
| id | doaj-art-5fc4834eb542452fa1ce111541ca8cee |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-5fc4834eb542452fa1ce111541ca8cee2024-12-04T09:49:47ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-01231997101010.1080/14760584.2024.2416229Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a reviewElmira Flem0Celine Mouawad1Arto A. Palmu2Heather Platt3Kelly D. Johnson4E. David McIntosh5Jacobo Abadi6Ulrike K. Buchwald7Kristen Feemster8Global Medical and Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USAGlobal Medical and Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USAReal World Evidence, FVR – Finnish Vaccine Research, Tampere, FinlandClinical Research, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USAValue & Implementation, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USAGlobal Medical and Scientific Affairs, Merck Research Laboratories, MSD, (UK) Limited, London, UKGlobal Medical and Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USAClinical Research, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USAGlobal Medical and Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USAIntroduction Infant immunization programs using pneumococcal conjugate vaccines (PCVs) have reduced the rates of pneumococcal disease through direct vaccine-induced protection in vaccinated children and through indirect protection in non-vaccinated children and adults.Areas covered This review summarizes current evidence on the indirect protection of adults conferred by pediatric pneumococcal vaccination, including the impact on invasive pneumococcal disease (IPD) incidence and mortality, pneumonia admissions, and nasopharyngeal carriage prevalence. Factors affecting indirect protection against IPD are also discussed.Expert opinion Pediatric immunization with PCVs has substantially decreased vaccine-serotype IPD and pneumonia through indirect protection in both older (≥65 years of age) and younger adults, including those with underlying medical conditions. However, serotype replacement by non-vaccine serotypes, the persistence of some vaccine serotypes, and divergence of serotypes between children and adults have limited the impact of pediatric PCV programs on adult populations. Designing complementary vaccines that leverage indirect protection from pediatric immunization and target the most prevalent adult serotypes may be a preferred strategy to maximize the public health impact of pneumococcal vaccination.https://www.tandfonline.com/doi/10.1080/14760584.2024.2416229Indirect protectionnasopharyngeal carriagepneumococcal diseasepneumoniapneumococcal conjugate vaccinePCV |
| spellingShingle | Elmira Flem Celine Mouawad Arto A. Palmu Heather Platt Kelly D. Johnson E. David McIntosh Jacobo Abadi Ulrike K. Buchwald Kristen Feemster Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review Expert Review of Vaccines Indirect protection nasopharyngeal carriage pneumococcal disease pneumonia pneumococcal conjugate vaccine PCV |
| title | Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review |
| title_full | Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review |
| title_fullStr | Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review |
| title_full_unstemmed | Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review |
| title_short | Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review |
| title_sort | indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination a review |
| topic | Indirect protection nasopharyngeal carriage pneumococcal disease pneumonia pneumococcal conjugate vaccine PCV |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2416229 |
| work_keys_str_mv | AT elmiraflem indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview AT celinemouawad indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview AT artoapalmu indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview AT heatherplatt indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview AT kellydjohnson indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview AT edavidmcintosh indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview AT jacoboabadi indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview AT ulrikekbuchwald indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview AT kristenfeemster indirectprotectioninadults18yearsofagefrompediatricpneumococcalvaccinationareview |